Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013 PR Newswire SAN FRANCISCO, Nov. 7, 2013 SAN FRANCISCO, Nov. 7, 2013 /PRNewswire/ --Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2013. Cash and investments in marketable securities at September 30, 2013 were $208.6 million as compared to $302.2 million at December 31, 2012. "Nektar continues to have a very productive year achieving significant milestones with both our partnered programs and proprietary pipeline," said Howard W. Robin, President and Chief Executive Officer of Nektar. "For naloxegol, the MAA in Europe and NDS in Canada are now accepted for filing and the NDA in the U.S. was submitted for filing in mid-September. Naloxegol could be the first once-daily oral peripheral opioid antagonist approved to treat opioid-induced constipation. BAX 855, Baxter's longer-acting PEGylated Factor VIII therapy, which is in Phase 3, remains on track for a 2014 BLA filing. Finally, while I am disappointed that the results from the Phase 2 efficacy study for NKTR-181 were confounded by an unusual placebo response, we are working with our advisors and the FDA to design an optimal Phase 3 program, which should start by the middle of 2014." Revenue in the third quarter of 2013 was $60.9 million as compared to $18.4 million in the third quarter of 2012. Year-to-date revenue for 2013 was $117.8 million as compared to $60.0 million in the first nine months of 2012. Revenues included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.5 million and $12.7 million in the third quarter and year-to-date for 2013, respectively, and $3.4 million in the third quarter and $6.9 million in the first nine months of 2012. This non-cash royalty revenue is offset by non-cash interest expense. The increases in revenue in the third quarter and first nine months of 2013 as compared to the same periods in 2012 are primarily due to a $25.0 million milestone achieved upon the acceptance of the naloxegol MAA filing in Europe as well as increased product sales. In addition, revenue in the first nine months of 2013 increased as compared to the same period in 2012 due to a $10.0 million milestone achieved upon the initiation of Phase 3 studies for Amikacin Inhale in April 2013. Total operating costs and expenses in the third quarter of 2013 were $67.4 million as compared to $51.3 million in the third quarter of 2012. Year-to-date total operating costs and expenses in 2013 were $202.0 million as compared to $157.9 million for the same period in 2012. Total operating costs and expenses increased primarily as a result of increased clinical development expenses. Research and development expenses in the third quarter of 2013 were $43.9 million as compared to $34.0 million in the third quarter of 2012. Year-to-date R&D expense for 2013 was $141.8 million as compared to $102.3 million for the same period in 2012. R&D expense was higher in the third quarter and the first nine monthsof 2013 as compared to the same periods in 2012 reflecting the costs of the Phase 3 study of etirinotecan pegol (NKTR-102) in metastatic breast cancer, the Phase 2 study of NKTR-181, preparation for the Phase 3 study of NKTR-181, the Phase 1 study of NKTR-192, and the production of devices for the Phase 3 study of Amikacin Inhale. General and administrative expense was $10.6 million in the third quarter of 2013 as compared to $10.1 million in the third quarter of 2012. G&A expense in the first nine months of 2013 was $30.7 million as compared to $30.8 million for the same period in 2012. Non-cash interest expense incurred in connection with the 2012 royalty monetization was $5.6 million and $16.6 million in the third quarter and first nine months of 2013, respectively, as compared to $5.5 million and $12.6 million in the third quarter and first nine months of 2012, respectively. Net loss in the third quarter of 2013 was $16.5 million or $0.14 per share as compared to a net loss of $43.5 million or $0.38 per share in the third quarter of 2012. Net loss in the first nine months of 2013 was $114.4 million or $0.99 per share as compared to a net loss of$118.9 million or $1.04 per share in the first nine months of 2012. Conference Call to Discuss Third Quarter 2013 Financial Results Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time today, Thursday, November 7, 2013. This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Monday, December 9, 2013. To access the conference call, follow these instructions: Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international) Passcode: 91919000 (Nektar Therapeutics is the host) In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call. About Nektar Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 development as a once- daily, oral tablet for the treatment of opioid-induced constipation. For naloxegol, the MAA in Europe and the NDS in Canada have been accepted for filing, and an NDA has been submitted for filing in the U.S. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. NKTR-181, a novel mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic molecule in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in a number of Phase 2 studies. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare to treat patients with Gram-negative pneumonia. Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia^® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS^® for hepatitis C and Amgen's Neulasta^® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 3 clinical development. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com. Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, the potential for health authority approvals of naloxegol, the projected timeframe in which the NKTR-181 Phase 3 clinical study would be commenced, the timing of regulatory filings with health authorities for BAX 855, and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, (i) our drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in previous preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials, regulatory approval decisions, and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) acceptance, review and approval decisions for new drug applications by health authorities is an uncertain and evolving process and health authorities retain significant discretion at all stages of the regulatory review and approval decision process; (iv) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; (v) patents may not issue from our patent applications our proprietary or partnered drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; (vi) the outcome of any existing or future intellectual property or other litigation related to our proprietary or partnered drug candidates; and (vii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission on November 7, 2013. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Nektar Investor Inquiries: Jennifer Ruddock/Nektar Therapeutics (415) 482-5585 Susan Noonan/SA Noonan Communications, LLC (212) 966-3650 NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) ASSETS September 30, December 31, ^(1) 2013 2012 Current assets: Cash and cash equivalents $ $ 65,411 25,437 Short-term investments 118,139 251,757 Accounts receivable 4,557 5,805 Inventory 15,076 18,269 Other current assets 4,759 13,363 Total current assets 207,942 314,631 Restricted cash 25,000 25,000 Property and equipment, net 65,082 72,215 Goodwill 76,501 76,501 Other assets 8,510 9,443 Total assets $ $ 383,035 497,790 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ $ 3,723 2,863 Accrued compensation 13,910 8,773 Accrued expenses 10,771 8,008 Accrued clinical trial expenses 15,239 17,500 Deferred revenue, current portion 21,300 21,896 Interest payable 3,167 7,083 Other current liabilities 12,803 12,414 Total current 80,913 78,537 liabilities Senior secured notes 125,000 125,000 Capital lease obligations, less current 9,007 11,607 portion Liability related to sale of future 125,167 128,266 royalties, less current portion Deferred revenue, less current portion 82,233 96,551 Deferred gain 1,748 2,404 Other long-term liabilities 9,217 8,407 Total liabilities 433,285 450,772 Commitments and contingencies Stockholders' equity (deficit) : Preferred stock - - Common stock 11 11 Capital in excess of par value 1,636,162 1,617,744 Accumulated other comprehensive (1,689) (357) loss Accumulated deficit (1,684,734) (1,570,380) Total stockholders' (50,250) 47,018 equity (deficit) Total liabilities and stockholders' $ $ equity (deficit) 383,035 497,790 (1) The consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include allof the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share information) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2013 2012 2013 2012 Revenue: Product sales $ 14,672 $ $ 36,806 $ 8,355 24,994 Royalty revenue 354 498 1,030 3,966 Non-cash royalty revenue related to sale of future 4,523 3,427 12,744 6,895 royalties License, collaboration and 41,360 6,132 67,195 24,190 other revenue Total revenue 60,909 18,412 117,775 60,045 Operating costs and expenses: Cost of goods sold 12,877 7,228 29,549 23,138 Research and development 43,914 34,016 141,762 102,302 General and 10,643 10,068 30,700 30,750 administrative Impairment of long-lived - - - 1,675 assets Total operating costs and 67,434 51,312 202,011 157,865 expenses Loss from operations (6,525) (32,900) (84,236) (97,820) Non-operating income (expense): Interest income 116 603 639 1,865 Interest expense (4,587) (5,697) (13,888) (10,807) Non-cash interest expense on liability related to sale (5,616) (5,487) (16,644) (12,641) of future royalties Other income (expense), 262 156 385 913 net Total non-operating expense, (9,825) (10,425) (29,508) (20,670) net Loss before provision for (16,350) (43,325) (113,744) (118,490) income taxes Provision for income taxes 193 222 610 439 Net loss $ $ $ (114,354) $ (118,929) (16,543) (43,547) Basic and diluted net loss per $ $ $ $ share (0.14) (0.38) (0.99) (1.04) Weighted average shares outstanding used in computing 115,812 114,915 115,557 114,699 basic and diluted net loss per share NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Nine Months Ended September 30, 2013 2012 Cash flows from operating activities: Net loss $ $ (114,354) (118,929) Adjustments to reconcile net loss to net cash used in operating activities: Non-cash interest expense on liability 16,644 12,641 related to sale of future royalties Non-cash royalty revenue related to sale (12,744) (6,895) of future royalties Stock-based compensation 13,165 12,015 Depreciation and amortization 10,882 10,810 Impairment of long-lived assets - 1,675 Other non-cash transactions 332 641 Changes in operating assets and liabilities: Accounts receivable 1,248 1,027 Inventory 3,193 (4,098) Other assets 6,817 10,593 Accounts payable 697 (401) Accrued compensation 5,137 (120) Accrued expenses 2,741 (465) Accrued clinical trial expenses (2,261) 1,247 Deferred revenue (14,914) (3,430) Interest payable (3,916) 1,528 Other liabilities (4,825) (219) Net cash used in operating activities (92,158) (82,380) Cash flows from investing activities: Maturities of investments 274,011 202,768 Purchases of investments (140,569) (126,609) Restricted cash - (25,000) Sale of investments - 5,378 Purchases of property and equipment (1,382) (5,744) Net cash provided by investing activities 132,060 50,793 Cash flows from financing activities: Payment of capital lease obligations (2,201) (1,773) (Repayment of) proceeds from sale of future royalties, net of $4.4 million transaction (3,000) 119,588 costs in 2012 Proceeds from issuance of senior secured - 78,006 notes, net of $4.4 million transaction costs Repayment of convertible subordinated - (172,407) notes Proceeds from shares issued under equity 5,253 3,177 compensation plans Net cash provided by financing activities 52 26,591 Effect of exchange rates on cash and cash 20 22 equivalents Net increase (decrease) in cash and cash 39,974 (4,974) equivalents Cash and cash equivalents at beginning of 25,437 15,312 period Cash and cash equivalents at end of period $ $ 65,411 10,338 Supplemental disclosure of cash flow information: Cash paid for interest $ $ 17,097 9,010 Retirement of convertible subordinated notes in $ $ exchange for senior secured notes - 42,548 SOURCE Nektar Therapeutics Website: http://www.nektar.com
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Press spacebar to pause and continue. Press esc to stop.